Head and neck squamous cell carcinomas (HNSCCs) are the eighth and thirteenth most common malignancy in the world for males and females, respectively, affecting up to 600 000 people each year. Among the various HNSCC subtypes, about 10% are oral squamous cell carcinoma (OSCC), which represents the most frequent of all oral neoplasms. It is estimated that more than 90% of all oral neoplasms are OSCC.^[@bib1],\ [@bib2]^ Despite the advances in therapeutic approaches, percentages of morbidity and mortality of OSCC have still not significantly improved during the last 30 years with the 5-year overall survival rate for patients with OSCC varying between 40 and 50%. Consumption of alcohol, tobacco, and betel nut as well as the infection by human papillomavirus^[@bib3],\ [@bib4],\ [@bib5]^ are considered risk factors that drive abnormal gene expression and contribute to the initiation and development of OSCC.^[@bib6],\ [@bib7]^

Fibroblast Activation Protein, Alpha (FAP) is a homodimeric integral membrane gelatinase belonging to the serine protease family. In a previous study, FAP was found to be selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. Exogenous FAP protein expression or FAP-overexpressing fibroblasts promoted cell proliferation and invasion in ovarian cancer and pancreatic cancer.^[@bib8],\ [@bib9]^

Several investigations have indicated that FAP is expressed in epithelium-derived tumor cells including breast cancer,^[@bib10]^ pancreatic cancer,^[@bib11]^ gastric cancer,^[@bib12]^ colorectal cancer,^[@bib13]^ and cervical cancer^[@bib14]^ and its elevated expression as an unfavorable factor promotes the poor progression for these cancers. However, the roles of endogenous FAP in such tumors were not reported. Thus, this study was designed to investigate the function and possible molecular basis of FAP in the pathogenesis of OSCC. Here, we demonstrated that FAP exerts an impact as a potential oncogene, which in turn contributes to the initiation and progression of OSCC.

Results
=======

Increased expression of FAP is unfavorable for OSCC prognosis
-------------------------------------------------------------

Protein expression levels of FAP were measured in samples of 84 archived paraffin-embedded OSCC tissues and 12 non-cancerous oral cavity epithelium tissues using immunohistochemical staining ([Figure 1--Ia--h](#fig1){ref-type="fig"}). FAP protein immunostaining was mainly found on the cell membrane and in the cytoplasm of OSCC cells ([Figure 1--II](#fig1){ref-type="fig"}). Furthermore, FAP expression in OSCC samples was relatively higher than in Benign samples (*P*\<0.0001) ([Table 1](#tbl1){ref-type="table"}). Further, we analyzed the relationship between clinicopathologic characteristics and FAP expression levels in individuals with OSCC ([Table 2](#tbl2){ref-type="table"}). Although we did not find a significant association of FAP expression levels with patient\'s age, sex, smoking status, alcohol, recurrence, tumor location, differentiation, and distant metastasis (M classification), we observed that the elevated expression level of FAP was markedly correlated with tumor size (T classification) (T1--T2 *versus* T3--T4) (*P*=0.027), lymph-node metastasis (N classification) (N0--N1 *versus* N2--N3) (*P*=0.015) and clinical stage (I--II *versus* III--IV) (*P*=0.014) in OSCC patients. To investigate the prognostic value of FAP expression for OSCC, the follow-up data of 84 OSCC patients for up to 5 years were used to assess the value of FAP for predicting patient survival in OSCC patients. Kaplan--Meier survival analysis revealed a correlation between FAP expression level and overall survival times (*P*=0.005) ([Figure 1--III](#fig1){ref-type="fig"}).

Stably downregulated or transiently silenced FAP expression suppresses cell proliferation *in vitro* and inhibits the growth of OSCC xenografts *in vivo*
---------------------------------------------------------------------------------------------------------------------------------------------------------

To evaluate the functional significance of FAP on cell proliferation, we used a lentiviral shRNA vector to specifically and stably knock down the expression of FAP in KB cell line. The effect of shRNA transfection on the expression of FAP was confirmed by RT-PCR and western blot analysis. The amount of FAP mRNA and protein, normalized by *β*-actin, was reduced up to 75% compared with the negative control cells ([Figure 2a](#fig2){ref-type="fig"}). Furthermore, we found that FAP knockdown in KB cells inhibited cell growth *in vitro*. The growth curves determined by MTT assay showed that suppressing FAP significantly reduced cell viability in comparison with sh-con cells ([Figure 2b](#fig2){ref-type="fig"}). Colony formation assay showed that suppressing FAP significantly reduced cell proliferation compared with sh-con cells ([Figure 2c](#fig2){ref-type="fig"}). Downregulated FAP expression in shRNA-FAP-1 and 2 cells inhibited cell-cycle transition from G1 to S compared with sh-con cells ([Figure 2d](#fig2){ref-type="fig"}). To assess the effect of FAP on OSCC growth *in vivo*, we injected FAP-depleted KB cells, or their control cells into nude mice subcutaneously, and then monitored tumor growth. External fluorescent images can provide invaluable real-time data in tracking cancer growth. The tumor formation rate of KB/shRNA-FAP-1 and -2 cells was significantly lower than that of KB/shRNA-con cells ([Figure 2e](#fig2){ref-type="fig"}).

Interestingly, similar results were also observed in small-interfering RNA (siRNA)-mediated suppression of FAP in OSCC cells. We found that knocking down endogenous FAP expression not only reduced the expression of FAP ([Figure 3a](#fig3){ref-type="fig"}), but also decreased cell proliferation ([Figure 3b](#fig3){ref-type="fig"}) and the G1/S transition in OSCC KB and Tca-8113 cells ([Figure 3c](#fig3){ref-type="fig"}), compared with their respective Si-Con-treated OSCC cells. Taken together, these results suggested that FAP significantly promoted cell growth *in vitro* and *vivo*.

Knockdown of FAP attenuates cell migration and invasion *in vitro* and *in vivo*
--------------------------------------------------------------------------------

To investigate the effects of FAP on cancer cell migration and invasive ability, we examined the cellular invasion, migration following silencing of FAP in KB and Tca-8113 cells. In a wound-healing assay, silencing of FAP markedly slowed cell migration at the edges of scratch wound of KB cells ([Figure 4a](#fig4){ref-type="fig"}). Quantitative analyses at 48 h confirmed a significant reduction in wound closure in FAP-silenced cells compared with empty vector-transfected control cells ([Figure 4a](#fig4){ref-type="fig"}). In addition, Matrigel invasion assay showed that KB cells with downregulated FAP were much less invasive than controls ([Figure 4b](#fig4){ref-type="fig"}). Next, we analyzed the adhesion ability of the FAP shRNA-treated KB cells using a solid-phase assay combined with the MTT assay. For the same surface-coated concentration of FN, adhesion of the FAP shRNA-treated cells was significantly higher than the control cells ([Figure 4c](#fig4){ref-type="fig"}). Alterations in the cellular cytoskeleton organization and polarity are also involved in tumor cell metastasis.^[@bib15]^ Therefore, we examined the cytoskeleton structures of the FAP shRNA-treated cells by the phalloidin staining and found that the 'feet\' of the FAP shRNA-treated cells was shortened and that the cellular polarity was weakened compared with the control cells ([Figure 4d](#fig4){ref-type="fig"}). To assess the effect of FAP on OSCC metastasis *in vivo*, FAP-depleted KB cells and their control cells were independently injected into the spleens of nude mice. Fluorescence images showed a few scattered metastatic nodules in livers of nude mice were formed in the mice injected with KB/shRNA-FAP-1 and 2 cells, while a variety of large clusters were observed in KB/shRNA-con cells. This is consistent with the H&E-stained liver sections showing extensively distributed large metastatic nodules in mice injected with KB/shRNA-con cells, while only a few scattered metastatic cells were observed on the section of the mice injected with KB/shRNA-FAP-1 and -2 cells ([Figure 4e](#fig4){ref-type="fig"}). Similar to the stably suppressed FAP expression results, suppressing FAP expression using siRNA-FAP also reduced cell migration, invasion, and adhesion ability in KB and Tca-8113 cells ([Figures 5a--c](#fig5){ref-type="fig"}).

FAP modulates the expression of multiple genes involved in the cell cycle, MMPs, and EMT in OSCC
------------------------------------------------------------------------------------------------

To obtain further insight into the mechanisms of FAP in OSCC cell proliferation, migration, and invasion, we examined protein levels of cell cycle, MMP, and EMT-associated genes in OSCC KB cells with stably suppressed FAP expression. Silencing endogenous FAP expression reduced the activation of pRb (Ser780) and oncogenic cell-cycle regulators including CCNE1, E2F1, and c-Myc, but elevated the expression of tumor suppressors such as p27 and p21. The expression of CDK4, CCND1, and total Rb was not affected ([Figure 6a](#fig6){ref-type="fig"}). Morphologic and phenotypic EMT-like changes are accompanied by the downregulation of epithelial marker E-cadherin and upregulation of mesenchymal markers, such as Vimentin, N-cadherin, MMP-2, and MMP-9.^[@bib16],\ [@bib17]^ We examined the expression of epithelial and mesenchymal markers in FAP-silenced KB cells and found decreased expression of MMP2, MMP9, and EMT-marker genes including Snail, Slug, N-cadherin, and Vimentin while E-cadherin expression increased ([Figure 6b](#fig6){ref-type="fig"}).

FAP regulates proliferation, migration, and invasion through PTEN/PI3K/Akt and Ras-ERK signaling pathways in OSCC cells
-----------------------------------------------------------------------------------------------------------------------

Mounting evidence indicates that cell cycle, EMT, and MMPs signaling are regulated by GSK3*β*, a downstream target of the PI3K/Akt and Ras-ERK signaling pathways.^[@bib18],\ [@bib19]^ We examined the effect of FAP on PTEN/PI3K/Akt and Ras-ERK signaling pathways and found that reduced FAP significantly decreased the expression of phosphorylated PI3K, AKT, MEK1/2, ERK1/2, and GSK3*β*, whereas total levels remained unchanged ([Figure 6c](#fig6){ref-type="fig"}). Meanwhile we also found that PTEN, an upstream target of the PI3K/Akt signaling pathway, was upregulated in FAP-suppressed cells. These results suggested that FAP is an upstream factor modulating the PTEN/PI3K/Akt and Ras-ERK signaling pathways in OSCC.

PTEN depletion or introduction of PTEN respectively enhances or decreases proliferation, migration, and invasion of OSCC cells *in vitro*
-----------------------------------------------------------------------------------------------------------------------------------------

To better understand the role of PTEN/PI3K/Akt and Ras-ERK signaling pathways in FAP-regulated growth and metastasis of OSCC cells, siRNA transfection was employed to knockdown PTEN expression in KB/shRNA-FAP-1 cells, which had silenced endogenous FAP expression. Knockdown efficiency was evaluated by both real-time qRT--PCR and western blotting ([Figure 7a](#fig7){ref-type="fig"}). MTT assay showed that PTEN knockdown increased the cell growth rate ([Figure 7b](#fig7){ref-type="fig"}). Matrigel invasion assay demonstrated that depletion of PTEN in KB/shRNA-FAP-1 cells strongly elevated cell invasion ([Figure 7c](#fig7){ref-type="fig"}). Wound-healing assay suggested the rate of wound healing was markedly higher in PTEN-downregulated KB/shRNA-FAP-1 cells than in controls ([Figure 7d](#fig7){ref-type="fig"}). These results suggested that knockdown of PTEN expression in KB/shRNA-FAP-1 cells could dramatically enhance proliferation, migration, and invasion. Inversely, introduction of wild-type PTEN (pEGFP-wt-PTEN) markedly reduced cell proliferation and invasion compared with mutant-type PTEN (pEGFP-G129R-PTEN) and empty vector (pEGFP-C1) in KB/shRNA-FAP-1 cells growth rate ([Figure 7e](#fig7){ref-type="fig"}) and cell invasion ([Figure 7f](#fig7){ref-type="fig"}).

Discussion
==========

In previous studies, FAP-*α* was found to be selectively and highly expressed on the surface of cancer-associated fibroblasts surrounding examined epithelial cancers including breast, colorectal, pancreatic, and lung cancers.^[@bib20],\ [@bib21],\ [@bib22],\ [@bib23]^ However, FAP was recently observed to be expressed in epithelium-derived tumor cells,^[@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14]^ which suggested that FAP expression in epithelium was associated with the pathogenesis. Interestingly, the role and molecular basis of FAP linking the initiation and development of these tumors have not been reported.

In this study, FAP was confirmed to be expressed in OSCC cells by western blotting and immunofluorescence, which represented an ideal model to study the role and molecular mechanisms of FAP. We found that stably decreased expression of FAP converted KB cells into less aggressive cells, with lower capability of cell-cycle G1/S transition, cell growth *in vitro* and *in vivo*, cell adhesion, migration, and invasion *in vitro* as wells as metastasis *in vivo*. Interestingly, similar results were also observed in siRNA-FAP-treated KB and Tca-8113 OSCC cells. Furthermore, we also found that shRNA-FAP-treated cells were shortened and the cellular polarity was weakened compared with control cells. These results together suggest that endogenous FAP expression acts as an oncogene in OSCC cells.

The biological functions of FAP found in this study provide a mechanistic basis in OSCC. It is well known that high proliferative activity of tumor cells is associated with the increased cell-cycle transition.^[@bib24]^ In this study, we observed that suppressing FAP expression blocked cell growth by inhibiting cell-cycle progression and modulating cell cycle-related factors including downregulating c-Myc, CCNE1, pRB, and E2F1 as well as upregulating p21 and p27 expression. There is accumulating evidence that the EMT confers adhesion, migration, invasion, and metastasis capacity, stemness and multidrug resistance in tumor cells.^[@bib25],\ [@bib26],\ [@bib27],\ [@bib28],\ [@bib29]^ Thus, EMT may have a critical role in tumor progression. In the present study, we showed that suppressed expression of FAP decreased OSCC cell adhesion, migration, invasion, and metastasis capacity and induced EMT by elevating expression of the epithelial marker E-cadherin and reducing expression of the mesenchymal markers N-cadherin and vimentin. Furthermore, transcription factors Slug and Snail were altered providing the first evidence that FAP is itself sufficient to induce the EMT. Finally, our findings also indicated that knocking down FAP expression attenuated the expression of MMP2 and MMP9, two key members of matrix metalloproteinase (MMP) family that facilitate cell invasion and metastasis in many tumors.^[@bib30],\ [@bib31],\ [@bib32]^

In previous reports, activated PI3K/AKT was documented as a classical signaling pathway inducing pGSK-3*β* expression, which stimulates c-Myc-mediated signaling of cell-cycle progression. This promotes cell proliferation,^[@bib33]^ increases the expression of Snail and Slug inducing EMT transition,^[@bib34],\ [@bib35]^ and elevates secretion of MMP2 and MMP9 facilitating cell invasion.^[@bib36]^ Our results suggest that inactivated PI3K/AKT signaling is responsible for shRNA-FAP-mediated suppression of tumor cell proliferation, adhesion, invasion, and EMT. In addition, it has a role in hypophosphorylation of GSK3b, attenuated expression of c-Myc, pRB, CCNE1, E2F1, Snail, Slug, Vimentin, N-cadherin, MMP2, MMP9, and elevated expression of p21, p27, and E-cadherin in OSCC cells. Further, PTEN,^[@bib37]^ a well-known tumor suppressor that inhibits the activation of PI3K/AKT,^[@bib38]^ was found to be upregulated in shRNA-FAP cells compared with control cells. Knocking down PTEN expression or introduction of PTEN gene could respectively increase or reduce the aggressive phenotypes in OSCC cells with stable suppression of FAP. These findings suggest that FAP-mediated inhibition of PTEN activates PI3K/AKT/GSK-3*β* signaling, which in turn induces cell proliferation, migration, invasion, and metastasis in OSCC.

ERK signaling is also a classical pathway that stimulates GSK-3*β* phosphorylation and further induces c-Myc-mediated cell-cycle signaling to promote cell proliferation. This also stimulates Snail-modulated EMT critical for cell migration, invasion, and metastasis. In this study, we also observed the inactivation of pMEK and pERK after knocking down FAP in OSCC cells compared with control cells. This result is similar to Yang *et al.*\'s report^[@bib8]^ and suggested that ERK signaling positively mediates FAP-stimulated cell growth and the EMT program.

FAP expression has been described to be present predominantly in cancer-associated fibroblasts of many human epithelial malignancies. Elevated expression of FAP was also associated with histological grade, invasion, and metastatic progression. In this study, we also examined the expression of FAP in OSCC tissues and evaluated the correlation of FAP expression with clinical features. Our findings suggest that FAP is expressed in OSCC cells and its overexpression is positively correlated with clinical progression of OSCC patients. We further analyzed the correlation of FAP expression in OSCC cells with patient survival. As expected, increased expression of FAP was associated with shorter overall survival in patients with OSCC. Together, FAP served as an independent prognostic indicator for OSCC.

In summary, we provided evidence that knocking down endogenous FAP suppresses cell proliferation, adhesion, migration, invasion, and metastasis by inactivating PTEN/PI3K/AKT and Ras-ERK signaling. This in turn inhibits GSK-3*β* and its downstream signals including cell-cycle regulators, EMT, and MMPs in OSCC. Furthermore, we observed that increased FAP expression facilitates the progression and poor prognosis of OSCC. Our studies demonstrated that FAP is a potential oncogene participating in OSCC pathogenesis.

Materials and Methods
=====================

Cell culture, tissue collection, and Ethics Statement
-----------------------------------------------------

OSCC cell lines KB and Tca-8113 were maintained in RPMI-1640 supplemented with 10% newborn calf serum (NBCS) (PAA Laboratories, Inc., Pasching, Austria). In all, 84 paraffin-embedded OSCC specimens and 12 paraffin-embedded non-cancerous control tissues were obtained at the time of diagnosis before any therapy from Nanfang Hospital of Southern Medical University, Guangzhou. In 84 cases, there were 54 males and 30 females with ages ranging from 31 to 83 years (mean age: 54.13 years). For the use of these clinical materials for research purposes, prior written informed consents from all the patients and approval from the Ethics Committees of Nanfang Hospital of Guangdong Province were obtained. All specimens had confirmed pathological diagnosis and were staged according to the 2009 UICC-TNM Classification of Malignant Tumors.

Establishment of lentivirus-delivered shFAP in OSCC cells
---------------------------------------------------------

The preparation of lentivirus expressing human FAP short hairpin RNA (shRNA-1247,1386) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}) was performed using the pLVTHM-GFP lentiviral RNAi expression system, which has been described in previous studies.^[@bib39],\ [@bib40]^ The lentiviral particles were used to infect OSCC cell lines KB, and the levels of OSCC protein expression were measured using western blot assays.

Plasmid construction and transfection
-------------------------------------

Eukaryotic expression vectors of the wild type (pEGFP-wt-PTEN) and the mutant type (pEGFP-G129R-PTEN) of PTEN were constructed by Guangzhou Sagene (Sagene Incorporation, Guangzhou, China). KB/shRNA-FAP-1 cells were transfected with empty vector (pEGFP-C1), the wild-type vector (pEGFP-wt-PTEN) and the mutant-type vector (pEGFP- G129R-PTEN) by Lipofectamine 2000. Culture medium containing G418 was used to select stable transfectants.

Transient transfection with siRNAs for FAP
------------------------------------------

siRNA for FAP and PTEN was designed and synthesized by Guangzhou RiboBio (RiboBio Inc., Guangzhou, PR China). The sequence of each gene and their controls are shown in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. Twenty-four hours before transfection, OSCC KB cells were plated onto a 96-well plate or a 6-well plate (Nest Biotechnology Co, Ltd., Shanghai, PR China) at a 30--50% confluence. They were then transfected into cells using TurboFect siRNA Transfection Reagent (Fermentas, Vilnius, Lithuania) according to the manufacturer\'s protocol. Cells were collected after 48--72 h for the further experiments.

RNA isolation, reverse transcription, and qRT-PCR
-------------------------------------------------

Total RNA was extracted from the shFAP and its mock cells using Trizol (Takara, Shiga, Japan). For FAP, RNA was transcribed into cDNA and amplified with specific sense: 5-TGTGCATTGTCTTACGCCCT-3; antisense primer: 5-CCGATCAGGTGATAAGCCGT-3. For PTEN gene, the forward (5-TGGATTCGACTTAGACTTGACCT-3) and reverse (5-TTGGCGGTGTCATAATGTCTT-3). Reverse transcription and QPCR were performed in accordance with manufacturer\'s instructions (Takara). The PCR for each gene was repeated three times. GAPDH was used as an internal control to normalize FAP expression. Differential expression of FAP was calculated using the 2^−ΔΔCt^ method.

Western blotting
----------------

Western blotting was performed using a SDS-PAGE Electrophoresis System according to the previous^[@bib39],\ [@bib40]^ description with rabbit polyclonal anti-FAP antibody (1 : 1000; LifeSpan BioSciences Inc., Seattle, WA, USA), anti-*β*-actin, CCND1, CDK4, p21, E2F1, and p27 (1 : 500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-C-Myc, PTEN, *β*-catenin, GSK-3b, p-GSK-3b(ser-9), p-Erk1/2(Tyr202/Tyr204),Erk1/2, p-MEK1/2 (Ser-217/221), MEK1,CCNE1, MMP2, MMP9, p-RB (ser780), RB, AKT, p-Akt (Ser-473), PI3K, p-PI3K (Tyr458), p16, p27, Slug, Snail, Vimentin, N-cadherin, and E-cadherin (1 : 1000; Cell Signaling Technology, Danvers, MA, USA). Signals were detected using enhanced chemiluminescence reagents (Pierce, Rockford, IL, USA).

Immunofluorescence
------------------

OSCC cells were seeded on coverslips in 6-well plate and cultured overnight. Subsequently cells were fixed in 3.5% paraformaldehyde, permeabilized in KB solution and 0.2% Triton X-100 at room temperature. After the blocking solution was washed out, cells were incubated with a primary antibody (FAP) (diluted in KB) 30--45 min at 37°C and subsequently washing with KB twice. After incubating 30--45 min at 37°C with secondary antibody (diluted in KB), washing with KB again, the coverslips were then mounted onto slides with mounting solution containing 0.2 *μ*g/ml DAPI and sealed with nail polish. The F-actin status was analyzed by phalloidin staining (Abbkine, Inc., Redlands, CA, USA) for 45 min at room temperature. Slides were stored at 4°C in a dark box and observed under a fluorescent microscope.

MTT assay
---------

3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was used to evaluate the rate of *in vitro* cell proliferation. For shFAP cells and siFAP cells, they were seeded in 96-well plates at a density of 1000 cells/well and respectively incubated for 1, 2, 3, 4, 5, 6, or 7 days or 1, 2, 3, 4, or 5 days. Twenty microliters of MTT (5 mg/ml) (Sigma, St. Louis, MO, USA) was added to each well and incubated for 4 h. At the end of incubation, the supernatants were removed, and 150 *μ*l of DMSO (Sigma) was added to each well. The absorbance value (OD) of each well was measured at 490 nm. Experiments were carried out three times.

Colony formation assay
----------------------

Cells were plated in 6-well culture plates at 200 cells/well. After incubation for 13 days at 37°C, cells were washed twice with PBS and stained with the Giemsa solution. The number of colonies containing ≥50 cells was counted under a microscope. The colony formation efficiency was calculated as (number of colonies/number of cells inoculated) × 100%.

Cell-cycle analysis
-------------------

For cell-cycle analysis, cells were seeded on 10 cm-diameter plates in RPMI-1640 containing 10% NBCS. After incubation for 48 h, a total of 5 × 10^6^ cells were harvested, rinsed with cold PBS, and fixed with 70% ice-cold ethanol for 48 h at 4°C. Fixed cells were rinsed with cold PBS followed by incubation with PBS containing 10 *μ*g/ml propidium iodide and 0.5 mg/ml RNase A for 30 min at 37°C. The DNA content of labeled cells was acquired using FACS cytometry (BD Biosciences Inc., Franklin Lakes, NJ, USA). Each experiment was performed in triplicate.

Wound-healing assay
-------------------

Cell migration was assessed using scratch-healing assays. Briefly, KB and Tca-8113 cells stably or transiently transfected with shRNA or siRNA and empty vectors were cultured in 6-well plates. When the cells grew to 90% confluence, three scratch wounds across each well were made using a *P*-200 pipette tip. Fresh medium supplemented with reduced (5%) fetal bovine serum was added, and the wound-closing procedure was observed for 48 h. Photographs were taken at 0 and 48 h, respectively.

Invasion assay
--------------

For the invasion assay, 1 × 10^5^ cells were seeded in 100 *μ*l RPMI-1640 media on the top of polyethylene terephthalate (PET) membranes coated with Matrigel TM (1.5 mg/ml, BD Biosciences Inc.) within transwell cell culture inserts (24-well inserts, 8 mm pore size; Corning Life Sciences, Corning, NY, USA). The bottom chamber was filled with 600 *μ*l RPMI-1640 media containing 20% FBS. The cells were incubated for 12 h at 37°C with 5% CO~2~. Subsequently, the cells were fixed in 2.5% (v/v) glutaraldehyde and stained with crystal violet. The invasive cells on the gel bottom were visualized under a microscope (Leica Inc., Wetzlar, Germany) and quantified by counting the number of cells in three randomly chosen fields at 200-fold magnification.

Solid-phase adhesion assay
--------------------------

The adhesion assay was performed using the tetrazolium-based colorimetric assay (MTT). Equal numbers of cells were seeded into 96-well plates that had been precoated with 1 mg/ml of fibronectin (FN) (Sigma Inc., Osterode am Harz, Germany). As a comparison, an equal number of cells were also seeded in plates coated with bovine serum albumin (1% w/v). After 1 h, the plates were immersed into PBS containing 1 mM MgCl~2~ to remove non adherent cells. The number of adherent cells was then measured by MTT assay and read at 490 nm. The OD values reflected the proportion of cells that adhered to the FN-coated 96-well plate. The rate of adhesion was calculated by the following equation: value of the OD of the experiment/value of the OD of the control × 100%.

*In vivo* tumor growth assay
----------------------------

Cells were harvested by trypsinization, washed twice with cold serum-free medium, and resuspended with serum-free medium. To evaluate cancer growth *in vivo*, 2 × 10^6^ KB/sh-con, KB/sh-FAP-1 and KB/sh-FAP-2 cells were independently injected subcutaneously into the left back and right back of 11 nude mice. After injection, fluorescence emitted by cells was collected and imaged with a whole-body GFP imaging system (Lighttools, Encinitas, CA, USA). IPP5.0 software (Cybermetics, Silver Spring, MD, USA) was used for analysis of whole-body optical images, which visualized real-time tumor growth and tumor area.

*In vivo* metastasis assays
---------------------------

To evaluate the *in vivo* lung and liver metastatic potential of cancer cells, 5 × 10^6^ KB/sh-con, KB/sh-FAP-1 and KB/sh-FAP-2 cells were injected into nude mice (*n*=5 for each group) through the spleen, respectively. Whole-body optical images were visualized to monitor primary tumor growth and formation of metastatic lesions. Two months later, all mice were killed, individual organs were removed, and metastatic tissues were analyzed by H&E staining.

Immunohistochemistry
--------------------

Examination of FAP expression in samples of OSCC and its control tissues by IHC has been previously described^[@bib39],\ [@bib40]^ with FAP antibody (1 : 80) as previously described. The stained tissue sections were reviewed and scored independently by two pathologists blinded to the clinical parameters. The staining score standard has also been described.^[@bib39],\ [@bib40]^ For statistical analysis of FAP expression in noncancerous tissues against OSCC tissues, staining scores of 0--4 and 5--6 were respectively considered to be low and high expression.

Statistical analysis
--------------------

SPSS 13.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad software (GraphPad Software, Inc., La Jolla, CA, USA) were used to analyze all data for statistical significance. The Chi-Square test was applied to the examination of relationship between FAP expression levels and clinicopathological characteristics. Two-tailed Student\'s *t*-test was used for comparisons of two independent groups. One-way ANOVA was used to determine the differences between groups for all *in vitro* analyses. A *P*-value of \<0.05 was considered as statistically significant.
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![FAP expression in oral squamous cell carcinoma (OSCC) is associated with poor prognosis. (**I**) FAP expression examination in OSCC and control tissues (a) Negative FAP expression in oral cavity epithelium; (b, c) Negative expression of FAP in OSCC tissues; (d, e) Weakly positive expression of FAP in OSCC tissues; (f, g, and h) Positive and strong positive expression of FAP in OSCC tissues; (**II**) Immunofluorescent images of KB and Tca-8113 cells stained for FAP (green) and 4′,6-diamidino-2-phenylindole (DAPI; blue) (magnification, × 400); (**III**) Kaplan--Meier survival analysis of overall survival in all patients. The log-rank test was used to calculate *P*-values](cddis2014122f1){#fig1}

![Stable suppression of FAP attenuates the growth of OSCC cells *in vitro* and *vivo*. (**a**) Stably knocking down decreased the expression of FAP in shRNA-FAP-1 and -2 cells compared with shRNA-con cells by real-time PCR and western blotting. *β*-Actin was used as a loading control. (**b**) MTT cell viability assays were performed on days 1--6 of KB cells stably expressing the shRNA-FAP-1 and 2 or shRNA-con vectors. (**c**) Colony formation assay was performed on KB cells stably expressing the shRNA-FAP-1 and -2 or shRNA-con vectors for 2 weeks. (**d**) Cell-cycle analysis of KB cells stably expressing the shRNA-FAP-1 and 2 or shRNA-con vectors. (**e**) External whole-body fluorescence images of KB/shRNA-FAP-1 and -2 and KB/shRNA-con mice obtained 30 days after injection. Representative photographs of H&E staining of primary cancer tissues are shown. Data are presented as mean±S.D. for three independent experiments \*\**P*\<0.01; \*\*\**P*\<0.001, compared with control](cddis2014122f2){#fig2}

![Transient suppression of FAP inhibits growth of OSCC cells *in vitro*. (**a**) Transiently knocking down FAP by siRNA reduced the expression of FAP by real-time PCR and western blotting. (**b**) MTT cell viability assays was performed on days 1--5 after the transfection of KB and Tca-8113 cells with either siRNA FAP-1 or the negative control. (**c**) Cell-cycle profiles were analyzed after KB and Tca-8113 cells were transfected with siRNA FAP-1 or the negative control for 48 h. Data are presented as mean±S.D for three independent experiments \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001, compared with control](cddis2014122f3){#fig3}

![Stable depletion of FAP suppresses cell migration and invasion *in vitro* and *vivo*. (**a**) Wound-healing assay showed KB cells stably expressing the shRNA-FAP-1 and -2 or shRNA-con vectors at 0 and 48 h after wounding. Bar chart showing the relative migration ability at 48 h. (**b)** Cell invasion assay showed decreased invasion from cells transfected with shRNA-FAP-1 and -2, with representative fields shown. (**c**) The ability of the cells to adhere to a solid surface was significantly increased in cells treated with shRNA-FAP-1 and -2, and a representative experiment is shown. Bar chart showing the adhesive rate quantified by MTT assay. (**d**). Phalloidin staining of F-actin in KB/shRNA-FAP-1 and KB/shRNA-con cells (magnification, × 1000). (**e**) External whole-body fluorescence images of liver were obtained 2 months after spleen injection, respectively. Metastatic cancer tissue (H&E staining, magnification, × 200). Data shown are means±S.D. of at least three independent experiments \**P*\<0.05; \*\**P*\<0.01, compared with control](cddis2014122f4){#fig4}

![Transient depletion of FAP reduces cell migration and invasion *in vitro*. (**a**) Transiently downregulated FAP dramatically inhibited KB and Tca-8113 cell migration *in vitro*. (**b**) Transiently suppressed FAP decreased *in vitro* invasiveness of KB and Tca-8113 cells. (**c**) Transient knockdown of FAP elevated the adhesion rate of KB and Tca-8113 cells. Data are presented as means±S.D. of at least three independent experiments \**P*\<0.05; \*\**P*\<0.01, compared with control](cddis2014122f5){#fig5}

![FAP regulates the expression of cell cycle, MMPs, and EMT-associated genes in OSCC through PTEN/PI3K/Akt and ERK signaling pathways. (**a**) Knocking down endogenous FAP expression reduced the activation of pRb(ser780), an oncogenic cell-cycle regulator including CCNE1, E2F1, and c-Myc, and elevated the expression of tumor suppressors including p27 and p21. However, the expression of CDK4, CCND1, and total Rb was not affected. (**b**) Suppressing FAP expression decreased the expression of MMP2, MMP9, and EMT-marker genes including Snail, Slug, N-cadherin, and Vimentin but increased E-cadherin expression. (**c**) Reduced FAP significantly decreased the expression of phosphorylated PI3K, AKT, MEK1/2, ERK1/2, and GSK3*β*, whereas total levels remained unchanged. *β*-Actin was used as a loading control](cddis2014122f6){#fig6}

![PTEN depletion or gain respectively elevates or decreases proliferation, migration, and invasion of cells with downregulated FAP. (**a**) Decreased PTEN mRNA and protein levels in KB cells with stably silenced FAP and transfected with siRNA were found by real-time PCR and western blotting. (**b**) MTT cell viability assays were performed on days 1--5 after the transfection of FAP knockdown KB cells with either siRNA PTEN-1 and -2 or the control. (**c**) Transiently downregulated PTEN dramatically enhanced the ability of KB cells treated with shRNA-FAP-1 invasion *in vitro*. (**d**) Transiently suppressed PTEN elevated *in vitro* migration of KB cells that had stable downregulated FAP. (**e**) MTT cell viability assays were performed on days 1--4 after the transfection of FAP knockdown KB cells with either the wild type (pEGFP-wt-PTEN) and the mutant type (pEGFP-G129R-PTEN) or empty vector (pEGFP-C1). (**f**) Introduction of PTEN decreased invasion of KB cells treated with shRNA-FAP-1. Data are presented as mean±S.D. for three independent experiments \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001, compared with control](cddis2014122f7){#fig7}

###### Immunohistochemistry analysis of FAP expression in OSCC

  **Group**                ***N***  **FAP expression (%)**   ***P*****-value**   
  ----------------------- --------- ------------------------ ------------------- ----------
  Non-cancerous tissues      12     11 (91.7%)               1 (8.3%)             \<0.0001
  Carcinoma                  84     31 (36.9%)               53 (63.1%)               

###### Correlation between expression of FAP protein and clinicopathological characteristics in OSCC patients (*n*=84)

             **Variables**              **FAP (%)**                                             
  ------------------------------------ ------------- --------------------- -------------------- -------------------
                                          ***n***     **High expression**   **Low expression**   ***P*****-value**
                *Gender*                                                                        
                  Male                      54            24 (44.4%)            30 (55.6%)                
                 Female                     30            11 (36.7%)            19 (63.3%)             0.645
                                                                                                          
             *Age (years)*                                                                      
                   ≥54                      35            15 (42.9%)            20 (57.1%)                
                  \<54                      49            17 (47.2%)            32 (52.8%)             0.813
                                                                                                          
               *Smoking*                                                                        
                   Yes                      38            18 (47.4%)            20 (52.6%)                
                   No                       46            16 (33.3%)            30 (66.7%)             0.267
                                                                                                          
                 *Site*                                                                         
                 Tongue                     38            25 (65.8%)            13 (34.2%)                
              Buccal mucosa                 24            16 (66.7%)            8 (33.3%)                 
                Gingival                    18            11 (61.1%)            7 (38.9%)                 
                  Other                      4              3 (75%)              1 (25%)               0.955
                                                                                                          
           *Differentiation*                                                                    
           Well differentiated              32            20 (62.5%)            12 (37.5%)                
    Moderate to poorly differentiated       52            38 (70.4%)            16 (29.6%)             0.483
                                                                                                          
               *Alcohol*                                                                        
                   Yes                      29            17 (58.6%)            12 (41.4%)                
                   No                       55            39 (70.9%)            16 (29.1%)             0.331
                                                                                                          
              *Recurrence*                                                                      
                   Yes                      19            12 (63.2%)            7 (36.8%)                 
                   No                       65            38 (58.5%)            27 (41.5%)             0.795
                                                                                                          
           *T classification*                                                                   
                  T1+T2                     48            21 (43.8%)            27 (56.2%)                
                  T3+T4                     26            19 (73.1%)            7 (26.9%)            **0.027**
                                                                                                          
           *N classification*                                                                   
                  N0+N1                     51            23 (45.1%)            28 (54.9%)                
                  N2+N3                     33            24 (72.7%)            9 (27.3%)            **0.015**
                                                                                                          
          *Distant metastasis*                                                                  
                   M1                        6             5 (83.3%)            1 (16.7%)                 
                   M0                       78            38 (55.9%)            30 (44.1%)             0.391
                                                                                                          
            *Clinical stage*                                                                    
                  I--II                     50            18 (36.0%)            32 (64.0%)                
                 III--IV                    34            22 (64.7%)            12 (35.3%)           **0.014**

Bold values indicate statistical significance, *P*\<0.05

[^1]: These authors contributed equally to this work.
